A randomized study of observation versus adjuvant low-dose extended duration interferon alpha-2A in completely resected high-risk malignant melanoma

Trial Profile

A randomized study of observation versus adjuvant low-dose extended duration interferon alpha-2A in completely resected high-risk malignant melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2005

At a glance

  • Drugs Interferon alpha (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AIM-HIGH
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top